Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Combretastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 known ✓ | Q9H4B7 | 9/20 | 0.70 |
| ▸ | TUBB4A known ✓ | P04350 | 8/20 | 0.70 |
| ▸ | TUBB known ✓ | P07437 | 8/20 | 0.70 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 8/20 | 0.70 |
| ▸ | TUBA1B known ✓ | P68363 | 8/20 | 0.70 |
| ▸ | TUBA4A known ✓ | P68366 | 8/20 | 0.70 |
| ▸ | TUBB4B known ✓ | P68371 | 8/20 | 0.70 |
| ▸ | TUBB3 known ✓ | Q13509 | 8/20 | 0.70 |
| ▸ | TUBB2A known ✓ | Q13885 | 8/20 | 0.70 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 8/20 | 0.70 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 8/20 | 0.70 |
| ▸ | TUBA1A known ✓ | Q71U36 | 8/20 | 0.70 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 8/20 | 0.70 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 8/20 | 0.70 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 8/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Combretastatin SCHEMBL3746076 | 0.90 | TUBB1 (0.72) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL19956 | 0.84 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL19955 | 0.84 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL30334938 | 0.84 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL29394501 | 0.84 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL29356562 | 0.84 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL5566666 | 0.84 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL4408635 | 0.83 | TUBB1 (0.87) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL6429578 | 0.83 | TUBB1 (0.97) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Combretastatin SCHEMBL6430650 | 0.83 | TUBB1 (0.97) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065358-B1 | THE PREPARTION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS | ZHEJIANG DADE PHARMACEUTICAL GROUP CO LTD (CN) | 2015-07-08 | — | — | EP | disclosed |
| US-7838706-B2 | Preparation and the use of ethoxy combretastatins and their prodrugs | ZHEJIANG DADE PHARMACEUTICAL GROUP CO. LTD (CN) | 2010-11-23 | — | — | US | disclosed |
| US-20090170956-A1 | PREPARATION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS | ZHEJIANG DADE PHARMACEUTICAL GROUP CO. LTD (CN) | 2009-07-02 | — | — | US | disclosed |
| EP-2065358-A1 | THE PREPARTION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS | Zhejiang Dade Pharmaceutical Group Co., Ltd. (CN) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170956-A1 | PREPARATION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS | PHOSPHO1, TUBB3, TYMP | TUBB1 5/4885TUBB4A 10/4885TUBB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.